Connor Clark & Lunn Investment Management Ltd. Sells 27,970 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX

Connor Clark & Lunn Investment Management Ltd. cut its position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 527,685 shares of the company's stock after selling 27,970 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.17% of AMNEAL PHARMACEUTICALS worth $4,422,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in shares of AMNEAL PHARMACEUTICALS by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after purchasing an additional 3,107 shares during the period. Headlands Technologies LLC purchased a new position in shares of AMNEAL PHARMACEUTICALS during the 1st quarter valued at $31,000. Amalgamated Bank grew its position in shares of AMNEAL PHARMACEUTICALS by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of AMNEAL PHARMACEUTICALS during the 4th quarter valued at $52,000. Finally, Xponance Inc. increased its stake in AMNEAL PHARMACEUTICALS by 16.1% in the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after acquiring an additional 1,828 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Insider Transactions at AMNEAL PHARMACEUTICALS

In related news, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the transaction, the executive vice president directly owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Andrew S. Boyer sold 33,436 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $302,595.80. Following the transaction, the executive vice president directly owned 256,670 shares of the company's stock, valued at $2,322,863.50. The trade was a 11.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 177,130 shares of company stock valued at $1,619,733 over the last 90 days. Company insiders own 17.45% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMRX. The Goldman Sachs Group began coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price on the stock. Wall Street Zen lowered AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $11.60.

AMNEAL PHARMACEUTICALS Stock Performance

Shares of NASDAQ:AMRX traded down $0.03 during trading on Monday, reaching $9.43. 380,682 shares of the stock traded hands, compared to its average volume of 1,687,093. The stock has a 50-day moving average of $8.21 and a two-hundred day moving average of $7.97. AMNEAL PHARMACEUTICALS, INC. has a 52-week low of $6.68 and a 52-week high of $9.59. The stock has a market cap of $2.96 billion, a P/E ratio of 941.44 and a beta of 1.11.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. Sell-side analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current year.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.